Second Genome, Inc.

Second Genome Home Page

Culture and Careers

Press Releases

Events

Bayer Collaboration Milestone Accomplished

Arena Pharmaceuticals Collaboration Announcement

Gilead Collaboration Announcement

NASH Collaboration with VCU

DDW 2022: Discovering Immunomodulatory Microbiome-Derived Peptides with Therapeutic Potential through Multi-Technology Meta-Analysis and Functional Assays

DDW 2022: SG-5-00455 Improves Epithelial Barrier Function and Promotes Mucosal Healing in IBD

SG-3-06686 overview SITCWorkshop

Virtual KOL Panel: SG-5-00455 and the Role of Mucosal Healing and PAI-1/2 in IBD

SG-5-00455: Development Candidate Targeting PAI-1/2 for IBD Treatment

Crohn's and Colitis Congress 2022, SG-5-00455

Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

Patent granted for SG proteins for the treatment of epithelial barrier function disorders

The Future of Immunotherapy Helena Kiefel, Head of Oncology

Crohn's & Colitis Foundation's® IBD Innovate Conference

SITC 2021 Preclinical Data: SG-3-00802 Targets a Key Mechanism Required for Efficacious Immunotherapy

Cold Spring Harbor Laboratory's Genome Informatics Conference

Second Genome Presents Preclinical Data for SG-3-0020 at the 2021 AACR-NCI-EORTC International Conference on Cancer Therapeutics

A novel microbiome-derived peptide, SG-3-00802 reverses resistance to anti-PD1 therapy

Second Genome Presents Preclinical Data at ESMO 2021

#closethecaregap

CC Personal Stories

The Power of Poop: Do Fecal Transplants Help Treat IBD?

Cell Press article